A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes

David F Lehmann et al. J Clin Pharmacol. 2008 Aug.

. 2008 Aug;48(8):999-1002.

doi: 10.1177/0091270008319791.

No abstract available

Similar articles

[The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
Szymborska-Kajanek A, Strojek K. Szymborska-Kajanek A, et al. Kardiol Pol. 2006 Mar;64(3):322-5; discussion 325-6. Kardiol Pol. 2006. PMID: 16583340 Review. Polish. No abstract available.
Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F, Caglayan E, Hsueh WA. Blaschke F, et al. Endocrinol Metab Clin North Am. 2006 Sep;35(3):561-74, ix. doi: 10.1016/j.ecl.2006.06.001. Endocrinol Metab Clin North Am. 2006. PMID: 16959586 Review.
Releasing the pressure.
Davenport RJ. Davenport RJ. Sci Aging Knowledge Environ. 2005 Jun 22;2005(25):nf47. doi: 10.1126/sageke.2005.25.nf47. Sci Aging Knowledge Environ. 2005. PMID: 15975897 No abstract available.
Actos and Avandia in type 2 diabetes. Where do they fit?
Clark W. Clark W. Diabetes Self Manag. 2007 Jul-Aug;24(4):8, 11-3. Diabetes Self Manag. 2007. PMID: 17663078 No abstract available.
Cardiovascular effects of the thiazolidinediones.
Qayyum R, Schulman P. Qayyum R, et al. Diabetes Metab Res Rev. 2006 Mar-Apr;22(2):88-97. doi: 10.1002/dmrr.596. Diabetes Metab Res Rev. 2006. PMID: 16184618 Review.